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ABSTRACT  
Besides enormous improvements in drug delivery, oral route has been highly and effectively utilized route of administration. Floating drug 
delivery that is also known to be low density system is advancement in the class of gastro-retentive drug delivery system. In the present 
research work, floating drug delivery of Rilpivirine hydrochloride was developed by overcoming various limitations and troubles associated 
with the drug including poor absorption in intestinal pH and degradation when comes in contact with higher pH environment.  [2] Prepared 
formulations were evaluated for various parameters like friability, hardness, thickness, drug content analysis, floating properties and in-vitro 
drug release study. Based on the evaluation, concluded that floating drug delivery system is a non-toxic as well as cost-effective technique for 
the rationale of enhancing bioavailability and absorption of poorly water soluble drugs. The improvement in gastric residence time is a clear 
sign. It can be able to use in the future for more acidic soluble drugs to enhance solubility and absorption.  
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INTRODUCTION: 
A virus that devastate the immune system of the body and 
causes Acquired Immuno Deficiency Syndrome (AIDS) is 
Human Immuno-deficiency Virus (HIV). Number of drugs 
are investigated to be anti-HIV.[1] The drugs like Rilpivirine 
appears to be most appropriate non- nucleoside reverse 
transcriptase inhibitor for the treatment of HIV-1 in adults 
because it has better tolerability which leads to less drug 
discontinuation and fewer side effects as compared to other 
NNRTIs. 
The main objective of the research work was to design a 
floating drug delivery system for Rilpivirine hydrochloride. 
The solubility and systemic absorption of Rilpivirine is pH 
dependent. It is demonstrated by an increased 
bioavailability in an acidic environment. [2] To improve the 
absorption of Rilpivirine by preventing the drug from 
alkaline environment, floating tablet was prepared. 
MATERIALS AND METHODS:  
Materials: Rilpivirine hydrochloride was received as a gift 
sample from Cipla Research and Development, Mumbai. 
HPMC, Sodium bicarbonate, crospovidone and 
microcrystalline cellulose were received from Smriti College 
of Pharmaceutical Education, Indore. Further chemicals used 
during formulation were analytical grade. 
Method:  
Preparation of Tablets:  
The active ingredient and excipients were weighed 
accurately and powder blend was directly compressed into 
tablet with the help of tablet punching machine consisting of 
25 mg of Rilpivirine hydrochloride. 
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Table 1: Composition of Floating Tablet 
Composition  F1(mg) F2(mg) F3(mg) F4(mg) F5(mg) F6(mg) 
Rilpivirine HCl  25 25 25 25 25 25 
HPMC  80 80 80 80 80 80 
Crospovidone 65 65 65 65 65 65 
Microcrystalline cellulose  70 70 85 70 70 70 
Magnesium stearate  25 25 25 25 25 25 
Sodium bicarbonate  60 50 40 40 35 25 
Citric acid  15 25 20 35 40 50 
Lactose  10 10 10 10 10 10 
Total weight  350 350 350 350 350 350 
 
Evaluation of prepared tablets: 
Weight variation: 
It was carried out to ensure the proper amount of drug in 
each tablet. 20 tablets were weighed individually with the 
help of analytical balance. The average weight was calculated 
and the percent weight variation was calculated with the 
help formula. 
% Weight Variation = (Individual weight – Average 
weight)/ Average weight x 100 
Hardness:  
The hardness of the tablet was determined with the help of 
Monsanto hardness tester and expressed in kg/cm2. 
Diameter and thickness: 
The diameter and the thickness of the tablet was measured 
with the help of vernier caliper and expressed in mm. 
Friability:  
Tablets equivalent to 6.5 gm were weighed and placed into 
the apparatus. They were exposed to rolling and repeated 
shocks as they fall from six inches in each turn within the 
apparatus. After 4 minutes or 100 revolutions, the tablets 
were reweighed and the loss due to abrasion was measured. 
Not more than 1% of the weight of the tablets is acceptable. 
% Friability = (W1-W2) / W1 x 100 
Here, W1 is the initial weight of tablet and W2 is the final 
weight of tablet. 
Floating properties of prepared formulations: 
The formulation was tested for floating properties like 
floating lag time and total floating time. Tablets were placed 
in a 100 ml beaker containing 0.1 N HCL (1.2 pH). The time 
required raising the tablet to the surface and show buoyancy 
was taken as the floating lag time. The total time interval of 
the tablet to float on the surface was taken as total floating 
time. 
Drug content: 
Tablets were randomly selected and crushed into mortar 
pestle. A suitable quantity of powder was extracted with 100 
ml of 0.1N HCl. This solution was filtered and analyzed under 
UV-spectrophotometer (Shimadzu 1800) at 315nm. 
In-vitro drug release: 
The drug release from the Rilpivirine hydrochloride floating 
tablets was investigated in a USP-II (paddle) apparatus. At 
predestined time intervals, aliquot were withdrawn and then 
analyzed under UV Spectrophotometer at λ max at 315 nm.
 
 
RESULTS: 
Table 2: Pre-compression studies of formulated floating tablets 
Formulation 
Code 
Bulk density 
(gm/mL) ±SD 
Tapped 
Density 
(gm/mL) ±SD 
Carr’s Index 
(%) ±SD 
Hausner’s 
Ratio 
Angle of repose 
(Ɵ) ±SD 
F1 0.412±0.009 0.612±0.014 12.7±0.08 1.48 25.55±0.91 
F2 0.317±0.01 0.367±0.02 13.24±0.13 1.15 22.33±0.88 
F3 0.374±0.006 0.542±0.018 11.81±0.18 1.44 25.55±0.86 
F4 0.296±0.03 0.320±0.03 14.65±0.06 1.08 21.12±0.54 
F5 0.296±0.03 0.391±0.07 13.63±0.04 1.32 26.71±0.46 
F6 0.327±0.03 0.389±0.04 14.56±0.04 1.18 25.07±0.41 
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TABLE 3:Post-compression studies of formulated floating tablets 
Batch 
Code 
Thickness 
(mm) ±SD 
Hardness 
(Kg/cm2) 
±SD 
Friability 
(%) 
Weight 
Variation 
(%) 
Floating 
Lag time 
(sec) 
Total 
Floating 
time (hrs) 
Drug 
Content (%) 
±SD 
F1 3.23±0.76 5.33±0.844 0.53 2.5±0.661 18 22 96.15±1.53 
F2 3.4±0.41 5.41±1.21 0.40 2.2±0.564 19 26.04 97.25±1.71 
F3 3.36±0.449 5±0.894 0.65 3.5±0.776 25 23 95.22±0.91  
F4 3.53±0.28 4.83±1.329 0.81 3.7±0.913 10 24.10 93.17±2.76  
F5 3.51±0.41 5.22±0.983 0.47 3.1±0.852 6 10 92.45±2.15  
F6 3.46±0.406 5.16±2.56 0.70 3.9±0.987 4 4.05 93.27±0.98  
 
 
 
Figure 1: Floating Tablet 
 
TABLE 4: Drug release profile of formulated floating tablets 
Time (hrs) Cumulative Drug Release of Prepared Formulation 
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 
0.5 hr 9.1±0.12 9.3±1.6 10.1±0.7 11.1±1.1 11.8±1.1 15.4±0.7 
1 hr 14.1±1.8 13.3±1.4 13.8±0.7 14.1±1.4 16.2±1.77 18.4±1.5 
2 hr 20.6±0.6 21.2±2.7 20.1±1.7 19.2±0.8 23.6±1.7 25.4±0.75 
3 hr 31.5±0.9 33.6±2.2 30.7±2.1 28.1±1.8 31.3±0.9 37.9±0.86 
4 hr 39.2±0.9 41.8±1.9 38.9±1.2 37.5±0.8 43.6±2.6 42.9±2.31 
5 hr 45.5±2.6 49.6±1.1 45.1±1.7 43.1±1.1 55.1±0.5 55.2±1.82 
6 hr 56.9±3.2 54.9±1.3 53.8±0.7 51.7±2.2 60.3±1.7 61.6±0.12 
18 hr 70.7±1.6 76.7±1.4 64.5±1.2 72.8±2.9 72.4±1.5 79.5±0.14 
20 hr 82.2±0.8 87.7±1.9 83.6±1.2 80.4±2.3 83.2±2.21 85.2±0.91 
24 hr 90.7±0.59 94.8±0.81 90.0±0.98 89.9±0.84 94.5±0.99 97.6±1.51 
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Dissolution study of formulated batches: 
The dissolution study of floating tablets were performed in 0.1 N HCl (1.2 pH) and observed results are depicted in the graph 
(Figure 2). 
 
Figure 2: In-vitro drug release study 
 
DISCUSSION: 
In this research work, the effervescent floating tablets of 
Rilpivirine HCl were successfully formulated using citric acid 
and sodium bicarbonate as gas forming agent and HPMC as 
film forming polymer. The identification tests of Rilpivirine 
HCl drug sample was done with the help of UV analysis, 
melting point determination, solubility studies, and IR and 
DSC tests. The observations recorded were identical to the 
values reported in literature. The evaluations of prepared 
floating tablet reveal encouraging result, because the 
prolonged gastric residence time is an enhancement in 
bioavailability. The optimized batch (F2) gave the best result 
in terms of in-vitro drug release rate and floating duration 
(>24 hrs). Sodium bicarbonate and citric acid were used in 
the ratio of 2:1 in optimized batch (F2), the release rate of 
this formulation was gradual enough to prolong the drug 
delivery and absorbed in gastric fluid. 
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